References of "Goudet, P"
     in
Bookmark and Share    
Full Text
See detailClinical and genetic studies in patients with Pituitary/Parathyroid variant of MEN1 without MEN1 gene mutation : the French GENEM collaborative study
VALDES SOCIN, Hernan Gonzalo ULg; Burlacu, C; Delemer, B et al

in Abstract Book - 13th International Workshop on Multiple Endocrine Neoplasia (2012, September)

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailAdrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database.
Gatta-Cherifi, B.; Chabre, O.; Murat, A. et al

in European Journal of Endocrinology (2012), 166(2), 269-279

Objective Limited data regarding adrenal involvement in multiple endocrine neoplasia type 1 (MEN1) is available. We describe the characteristics of MEN1-associated adrenal lesions in a large cohort to ... [more ▼]

Objective Limited data regarding adrenal involvement in multiple endocrine neoplasia type 1 (MEN1) is available. We describe the characteristics of MEN1-associated adrenal lesions in a large cohort to provide a rationale for their management. Methods Analysis of records from 715 MEN1 patients from a multicentre database between 1956 and 2008. Adrenal lesions were compared with those from a multicentre cohort of 144 patients with adrenal sporadic incidentalomas. Results Adrenal enlargement was reported in 20.4% (146/715) of patients. Adrenal tumours (>10 mm in size) accounted for 58.1% of these cases (10.1% of the whole patient cohort). Tumours were bilateral and >40 mm in size in 12.5 and 19.4% of cases respectively. Hormonal hypersecretion was restricted to patients with tumours and occurred in 15.3% of them. Compared with incidentalomas, MEN1-related tumours exhibited more cases of primary hyperaldosteronism, fewer pheochromocytomas and more adrenocortical carcinomas (ACCs; 13.8 vs 1.3%). Ten ACCs occurred in eight patients. Interestingly, ACCs occurred after several years of follow-up of small adrenal tumours in two of the eight affected patients. Nine of the ten ACCs were classified as stage I or II according to the European Network for the Study of Adrenal Tumors. No evident genotype/phenotype correlation was found for the occurrence of adrenal lesions, endocrine hypersecretion or ACC. Conclusions Adrenal pathology in MEN1 differs from that observed in sporadic incidentalomas. In the absence of relevant symptoms, endocrine biology can be restricted to patients with adrenal tumours and should focus on steroid secretion including the aldosterone-renin system. MEN1 is a high-risk condition for the occurrence of ACCs. It should be considered regardless of the size of the tumour. [less ▲]

Detailed reference viewed: 21 (0 ULg)
Full Text
Peer Reviewed
See detailGender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d''etude des Tumeurs Endocrines
goudet, p; Bonithon-Kopp, C.; Murat, A. et al

in European Journal of Endocrinology (2011)

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailRisk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.
Goudet, P.; Murat, A.; Binquet, C. et al

in World Journal of Surgery (2010), 34(2), 249-255

Background - The natural history of multiple endocrine neoplasia type 1 (MEN1) is known through single-institution or single-family studies. We aimed to analyze the risk factors and causes of death in a ... [more ▼]

Background - The natural history of multiple endocrine neoplasia type 1 (MEN1) is known through single-institution or single-family studies. We aimed to analyze the risk factors and causes of death in a large cohort of MEN1 patients. Methods - Overall, 758 symptomatic MEN1 patients were identified through the GTE network (Groupe d’étude des Tumeurs Endocrines), which involves French and Belgian genetics laboratories responsible for MEN1 diagnosis and 80 clinical reference centers. The causes of death were analyzed. A frailty model, including time-dependent variables, was used to assess the impact of each clinical lesion, except for hyperparathyroidism, on survival. Results - The median follow-up was 6.3 years. Female gender, family history of MEN1, and recent diagnosis were associated with a lower risk of death. Compared with nonaffected patients, those with thymic tumors (hazard ratio [HR] = 4.64, 95% CI = 1.73-12.41), glucagonomas–vipomas–somatostatinomas (HR = 4.29, 95% CI = 1.54-11.93), nonfunctioning pancreatic tumors (HR = 3.43, 95% CI = 1.71-6.88), and gastrinoma (HR = 1.89, 95% CI = 1.09-3.25) had a higher risk of death after adjustment for age, gender, and diagnosis period. The increased risk of death among patients with adrenal tumors was not significant, but three patients died from aggressive adrenal tumors. Pituitary tumors, insulinomas, and bronchial tumors did not increase the risk of death. The proportion of MEN1-related deaths decreased from 76.8 to 71.4% after 1990. Conclusions - The prognosis of MEN1 disease has improved since 1980. Thymic tumors and duodenopancreatic tumors, including nonsecreting pancreatic tumors, increased the risk of death. Rare but aggressive adrenal tumors may also cause death. Most deaths were related to MEN1. New recommendations on abdominal and thoracic imaging are required. [less ▲]

Detailed reference viewed: 28 (2 ULg)
See detailAssociation Acromégalie - Hyperparathyroïdie primaire : Néoplasie endocrinienne multiple de type 1 (NEM1) ou une nouvelle entité? Une étude du groupe de tumeurs neuroendocriniennes (GTE)
Valdes Socin, Hernan Gonzalo ULg; Delemer, B.; Burlacu, M. et al

in 23ème Congrès de la Société Française d'Endocrinologie - Abstract book (2006)

Detailed reference viewed: 37 (1 ULg)
Full Text
Peer Reviewed
See detailPituitary disease in MEN type 1 (MEN1): Data from the France-Belgium MEN1 multicenter study
Vergès, B.; Boureille, F.; Goudet, P. et al

in Journal of Clinical Endocrinology and Metabolism (2002), 87(2), 457-465

To date, data on pituitary adenomas in MEN type 1 (MEN1) still have to be evaluated. We analyzed the data of a large series of 324 MEN1 patients from a French and Belgian multicenter study. Data on ... [more ▼]

To date, data on pituitary adenomas in MEN type 1 (MEN1) still have to be evaluated. We analyzed the data of a large series of 324 MEN1 patients from a French and Belgian multicenter study. Data on pituitary disease were compared with those from 110 non-MEN1 patients with pituitary adenomas, matched for age, year of diagnosis, and follow-up period. Genetic analysis of the MEN1 gene was performed in 197 of the MEN1 patients. In our MEN1 series, pituitary disease occurred in 136 of 324 (42%), less frequently than hyperparathyroidism (95%, P < 0.001) and endocrine enteropancreatic tumors (54%, P < 0.01). Mean age of onset of pituitary tumors was 38.0 +/- 15.3 yr (range, 12-83 yr). Pituitary disease was associated with hyperparathyroidism in 90%. of cases, with enteropancreatic tumors in 47%, with adrenal tumors in 16%, and with thoracic neuroendocrine tumors in 4%. Pituitary disease was the initial lesion of MEN1 in 17% of all MEN1 patients. MEN1 pituitary adenomas were significantly more frequent in women than in men (50% vs. 31%,P < 0.001). Among the 136 pituitary adenomas, there were 85 prolactinomas and 12 GH-secreting, 6 ACTH-secreting, 13 cosecreting, and 20 nonsecreting tumors. Eighty-five percent of MEN1-related pituitary lesions were macroadenomas (vs. 42% in non-MEN1 patients, P < 0.001), including 32% of invasive cases. Among secreting adenomas, hormonal hypersecretion was normalized, after treatment, in only 42% (vs. 90% in non-MEN1 patients, P < 0.001), with a median follow-up of 11.4 yr. No correlation was found between the type of MEN1 germ-line mutation and the presence or absence of pituitary adenoma. Our study, based on a large group of MEN1 patients, shows that pituitary adenomas occur in 42% of the cases and are characterized by a larger size and a more aggressive presentation than without MEN1. [less ▲]

Detailed reference viewed: 71 (4 ULg)
Peer Reviewed
See detailHyperparathyroidism in multiple endocrine neoplasia type 1 : Surgical trends and results : a 256-patient series from the genem study group
Goudet, P.; Cougard, P.; Verges, B. et al

in World Journal of Surgery (2001), 25(7), 886-890

Detailed reference viewed: 7 (0 ULg)
Peer Reviewed
See detailLes insulinomes dans les néoplasies endocriniennes multiples de type 1 (NEM1) : A propos d'une série de 44 cas du Groupe d'Etude des Néoplasies Endocriniennes Multiples (GENEM)
Cougard, P.; Goudet, P.; Peix, J. L. et al

in Annales de Chirurgie (2000), 125(2), 118-123

Detailed reference viewed: 11 (0 ULg)
See detailClinical and genetic aspects of MEN1 and related diseases : a 3 year experience based on the French-Belgian Study group on MEN1
Calender, A.; Murat, A.; Carpentier, B. et al

in 6th International Workshop on Multiple Endocrine Neoplasia and Von Hippel-Lindau Disease (1997)

Detailed reference viewed: 4 (0 ULg)